Checchi Capital Advisers LLC Has $837,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Checchi Capital Advisers LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 25.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,539 shares of the biopharmaceutical company’s stock after selling 10,486 shares during the quarter. Checchi Capital Advisers LLC’s holdings in Pfizer were worth $837,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in PFE. Swedbank AB boosted its holdings in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Pallas Capital Advisors LLC lifted its position in shares of Pfizer by 54.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 9,102 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Pfizer by 132.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,361 shares of the biopharmaceutical company’s stock valued at $589,000 after buying an additional 11,615 shares in the last quarter. Integrated Advisors Network LLC grew its position in Pfizer by 18.3% in the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock valued at $1,853,000 after acquiring an additional 9,925 shares during the period. Finally, Fidelis Capital Partners LLC raised its stake in Pfizer by 5.2% during the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock worth $746,000 after acquiring an additional 1,267 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PFE. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Trading Down 1.3 %

PFE opened at $26.40 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $149.63 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm has a 50 day simple moving average of $26.34 and a 200 day simple moving average of $27.36. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.51%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.